SINGAPORE – Terumo Blood and Cell Technologies today launches the Advanced Therapy Manufacturing and Innovation (ATMI) Grant 2020 for the Asia Pacific region.
The ATMI Grant 2020 aims to accelerate advanced cell therapy manufacturing and development, with an award of up to USD 50,000 to principal investigators, scientists, researchers and clinicians exclusively from the Asia Pacific region to support the creative exploration of new and novel applications with the Quantum® Cell Expansion System. Terumo Blood and Cell Technologies is a global leader offering devices and products that collect and process blood and cells. Quantum is part of the company's growing presence in the cell and gene therapy space.
The field of cell and gene therapy is growing rapidly and is constantly evolving. Scientists can help advance their pursuit of innovation through collaboration, learning and exchange opportunities. I look forward to bright talents applying for the ATMI Grant 2020, enabling breakthrough research from our region.
-Dr. Yu Lei, a pioneer in the gene therapy field and Chief Executive Officer
UniCAR-Therapy Bio-Medicine Technology Co. of China
The ATMI Grant 2020 seeks to advance the translational research and process transfer, process development and novel application of cell and gene therapy technologies to further clinical manufacturing potential. This will be achieved through a one-year research collaboration between Terumo Blood and Cell Technologies and the successful applicant. In addition to the financial award, one Quantum device and up to 12 single-use sets will be provided to the grant recipient to use in conjunction with the ATMI project aimed at supporting new and novel applications with the Quantum device.
The cell and gene therapy space in Asia Pacific is witnessing an unprecedented growth in tandem with global trends. Through the ATMI Grant 2020, we are harnessing the potential seen across the Asia Pacific region. This inaugural grant forms part of our broader strategies that include research and development investments into robust manufacturing and performance-focused solutions to ultimately
touch patients' lives.
-Lei Li, Vice President, APAC Commercial, Terumo Blood and Cell Technologies
The ATMI Grant 2020 is open to applicants from universities, research institutes, academic centers, hospitals and biotech companies in the Asia Pacific region. Early applicants will have access to live webinar sessions with Dr. Yu Lei and Terumo Blood and Cell Technologies field application scientists. Later registrants will have access to a recording of the webinar.
Grant applications will be reviewed by Terumo Blood and Cell Technologies' Medical Affairs Department. Considerations include scientific and clinical merit and the applicant's track record. Visit www.terumobct.com/atmi-grant to learn more and apply. Applications will be collected from now until 17 November 2020 at 23:59 Singapore time.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical device company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our associates around the world believe in the potential of blood and cells to do even more for patients than they do today. TERUMOBCT.COM